Wednesday, August 25, 2010
Abstract: Perforation of a malignant ovarian tumor into the recto-sigmoid colon
Abstract
Ovarian cancer often presents at an advanced stage, but tends to be an intra-peritoneal disease that respects peritoneal planes. Thus, colo-rectal perforation of the tumor is an extremely rare presentation. The surgical treatment of malignant colo-ovarian fistula should include complete cyto-reduction at the same time as the treatment of the fistula. However, prognosis remains poor, because of the advanced stage of neoplasia. We report the case of a patient with an ovarian malignant tumor perforating into the recto-sigmoid colon. CT scan was the cornerstone of the radiological diagnosis. We managed to perform a complete cyto-reduction, including an en-bloc resection of the uterus, the mass, adnexa and recto-sigmoid with removal of the associated pelvic abscess.
Abstract:
Ovarian teratoma is a type of germ cell tumour. Germ cell tumours are cancers that begin in egg cells in women or sperm cells in men. There are two main types of ovarian teratoma
* Mature teratoma, which is benign
* Immature teratoma, which is cancerous
Background: The most common type of ovarian germ cell tumor is the teratoma. Thyroid tissue, both benign and malignant, may be a component of an ovarian teratoma. Here we review this topic and illustrate major features by presenting multimodal management of a patient with BRAF-positive disseminated follicular thyroid cancer arising in an ovarian teratoma.
Conclusions: Aggressive multimodal management appears to be the most promising approach for malignant thyroid tissue arising in ovarian teratomas.
in research - Abstract: RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells.
CONCLUSIONS: Our data provides kinase targets that could be exploited to design better therapeutics for ovarian cancer patients. We also demonstrate the effectiveness of high-throughput RNAi screening as a tool for identifying sensitizing targets to known and established chemotherapeutic agents.
News - August 2010 - National Breast and Ovarian Cancer Centre (NBOCC) Australia
 | ||||
| Australian: ovarian cancer clinical practice guidelines (teal star) |
Note: again with this update, the Australian ovarian cancer guidelines are in plain english and comprehensive; chapter 4 discusses briefly familial risks noting that HNPCC (hereditary non polyposis colorectal cancer) is now more commonly known as Lynch Syndrome; it would have been preferable to include the actual Lynch Syndrome commonly screened mutations (MSH2/MSH6/MLH1 & PMS2)
Promoting clinical best practice in the treatment of ovarian cancer:
NBOCC is currently reviewing and updating selected topics in its Clinical practice guidelines for the management of women with epithelial ovarian cancer, to provide Australian health professionals with timely, evidence-based information.....A evidence review has been completed to inform the development of updated recommendations about the follow-up care of women with ovarian cancer, including patient preferences
article/opinion piece: Canadian medical Association - CMA Emerges Dazed from Cave, Writes Report :: Longwoods.com
About the Author
Steven Lewis, President Access Consulting Ltd., Saskatoon & Adjunct Professor of Health Policy, University of Calgary and Simon Fraser University
Checking it twice: an evaluation of checklists for detecting medication errors at the bedside using a chemotherapy model - patient safety
Main outcome measures
Rates of specified types of errors related to medication administration.
Results
As few as 0% and as many as 90% of each type of error were detected.
Body Mass Index Increases Risk of Colorectal Adenomas in Men With Lynch Syndrome: The GEO Lynch Cohort Study
CONCLUSION Excess body weight increased the risk of incident colorectal adenomas in people with LS (Lynch Syndrome). This increased risk was seen only in men.
Subscribe to:
Posts
(
Atom
)
Posts
